Literature DB >> 28638742

An epigenetic modifier triggers therapeutic immune responses against breast cancer.

Lorenzo Galluzzi1,2, Guido Kroemer2,3,4,5,6,7,8.   

Abstract

Entities:  

Keywords:  CD8+ cytotoxic T cells; PD-1; TMP195; chemotherapy; immune checkpoint blockade; tumor-associated macrophages

Year:  2017        PMID： 28638742      PMCID： PMC5467991          DOI： 10.1080/2162402X.2017.1313376

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


× No keyword cloud information.
  11 in total

Review 1.  Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Authors:  Erika Vacchelli; Norma Bloy; Fernando Aranda; Aitziber Buqué; Isabelle Cremer; Sandra Demaria; Alexander Eggermont; Silvia Chiara Formenti; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-07-25       Impact factor: 8.110

Review 2.  Impact of myeloid cells on the efficacy of anticancer chemotherapy.

Authors:  Laura Senovilla; Fernando Aranda; Lorenzo Galluzzi; Guido Kroemer
Journal:  Curr Opin Immunol       Date:  2014-06-18       Impact factor: 7.486

3.  Macrophage Metabolism Shapes Angiogenesis in Tumors.

Authors:  Alberto Mantovani; Massimo Locati
Journal:  Cell Metab       Date:  2016-11-08       Impact factor: 27.287

Review 4.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

5.  Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.

Authors:  Jennifer L Guerriero; Alaba Sotayo; Holly E Ponichtera; Jessica A Castrillon; Alexandra L Pourzia; Sara Schad; Shawn F Johnson; Ruben D Carrasco; Suzan Lazo; Roderick T Bronson; Scott P Davis; Mercedes Lobera; Michael A Nolan; Anthony Letai
Journal:  Nature       Date:  2017-03-08       Impact factor: 49.962

6.  TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy.

Authors:  Stephen L Shiao; Brian Ruffell; David G DeNardo; Bruce A Faddegon; Catherine C Park; Lisa M Coussens
Journal:  Cancer Immunol Res       Date:  2015-02-25       Impact factor: 11.151

Review 7.  Natural and therapy-induced immunosurveillance in breast cancer.

Authors:  Guido Kroemer; Laura Senovilla; Lorenzo Galluzzi; Fabrice André; Laurence Zitvogel
Journal:  Nat Med       Date:  2015-10       Impact factor: 53.440

8.  Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy.

Authors:  Stephen Mok; Richard C Koya; Christopher Tsui; Jingying Xu; Lídia Robert; Lily Wu; Thomas Graeber; Brian L West; Gideon Bollag; Antoni Ribas
Journal:  Cancer Res       Date:  2013-11-18       Impact factor: 12.701

Review 9.  Tumour-associated macrophages as treatment targets in oncology.

Authors:  Alberto Mantovani; Federica Marchesi; Alberto Malesci; Luigi Laghi; Paola Allavena
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675

10.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression.

Authors:  Stephanie M Pyonteck; Leila Akkari; Alberto J Schuhmacher; Robert L Bowman; Lisa Sevenich; Daniela F Quail; Oakley C Olson; Marsha L Quick; Jason T Huse; Virginia Teijeiro; Manu Setty; Christina S Leslie; Yoko Oei; Alicia Pedraza; Jianan Zhang; Cameron W Brennan; James C Sutton; Eric C Holland; Dylan Daniel; Johanna A Joyce
Journal:  Nat Med       Date:  2013-09-22       Impact factor: 53.440
View more
  1 in total

Review 1.  Trial watch: dietary interventions for cancer therapy.

Authors:  Sarah Lévesque; Jonathan G Pol; Gladys Ferrere; Lorenzo Galluzzi; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2019-04-03       Impact factor: 8.110
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.